Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelly Olsen

Urology Mount Laurel, NJ Doctor of Osteopathy

NPI 1407340433 CMS profile 5241316

15000 Midlantic Dr, Mount Laurel, NJ 08054

Open in the dashboard

General payments

$3,423

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Olsen of Mount Laurel, NJ is reported in the CMS Open Payments database as having received $3,423 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $98 4
2024 General $451 8
2023 General $405 7
2022 General $607 8
2021 General $566 7
2020 General $128 1
2019 General $1,167 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Olsen
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Kelly Olsen were reported at $98. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Kelly Olsen Urology median Middle half National median
2019 $1,167 $480 $147–$1,201 $163
2020 $128 $246 $87–$645 $114
2021 $566 $358 $111–$1,000 $132
2022 $607 $476 $143–$1,263 $149
2023 $405 $560 $168–$1,461 $160
2024 $451 $563 $170–$1,464 $164
2025 $98 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $755 12 payments
  2. Olympus Corporation of the Americas $754 9 payments
  3. Medical Device Business Services, Inc. $245 2 payments
  4. Olympus America Inc. $223 2 payments
  5. PROCEPT BioRobotics Corporation $190 1 payment
  6. Janssen Scientific Affairs, LLC $183 2 payments
  7. Teleflex LLC $173 4 payments
  8. Axonics Modulation Technologies, Inc. $145 3 payments
  9. Blue Earth Diagnostics Limited $131 2 payments
  10. Astellas Pharma US Inc $115 1 payment
  11. Other $511 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,494 43 payments
  2. Travel and Lodging $595 5 payments
  3. Education $335 3 payments
Products named General payments · program years 2019–2025
  1. Olympus Cystoscopes $754 9 payments
  2. ShockPulse - SE $754 9 payments
  3. VISERA ELITE $754 9 payments
  4. ERLEADA $286 4 payments
  5. AQUABEAM SYSTEM $190 1 payment
  6. Axonics $159 4 payments
  7. UroLift System $152 3 payments
  8. LithoVue LithoVue_URO $143 1 payment
  9. Axumin $131 2 payments
  10. LITHOVUE Pain Management $125 1 payment
  11. Other $781 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

822

Median for Urology: 1,053

Drug cost

$86,285

Median for Urology: $101,464

Branded share of claims

43.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 66 $42,720
Gemtesa Vibegron Brand 47 $30,496
Estradiol Generic 53 $2,480
Methenamine Hippurate Generic 33 $1,924
Tolterodine Tartrate Er Tolterodine Tartrate Brand 28 $1,455
Oxybutynin Chloride Er Oxybutynin Chloride Brand 77 $1,402
Tamsulosin Hcl Generic 122 $1,246
Trospium Chloride Generic 27 $1,162
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 37 $1,052
Finasteride Generic 64 $514

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$156,880

Of which drugs: $5,698

Medicare patients

586

Average age 76

Services billed

4,331

299 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 37%
Ischemic heart disease 36%
Chronic kidney disease 32%
Atrial fibrillation 25%
Cancer 24%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record